Year: 2019
Type: editorial
Abstract: Immune checkpoint inhibitors (ICIs) targeting the programmed death 1/programmed death-ligand 1 (PD1/PD-L1) pathway have revolutionized treatment for various cancers. Evasion of the immune system is one of the hallmarks of cancer and chronic inflammation can facilitate cancer progression.
Source: Journal of Thoracic Disease
Authors: Christos Fountzilas, Steven N. Hochwald
Institution: Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2902169373